Skip to content

Cauterization Versus fibrin Glue for Conjunctival Autografting in Primary Pterygium Surgery

Cauterization Versus fibrin Glue for Conjunctival Autografting in Primary Pterygium Surgery

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03321201
Enrollment
164
Registered
2017-10-25
Start date
2018-05-08
Completion date
2026-12-31
Last updated
2022-11-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pterygium of Conjunctiva and Cornea

Brief summary

Pterygium is a noncancerous growth of the conjunctival tissue over the cornea. It is a progressive disease that may lead to visual impairment in advanced stages, as well as restriction of ocular motility, chronic inflammation and cosmetic concerns. Surgical removal is the treatment of choice, but recurrence of pterygium is a frequent problem. In this randomized controlled cauterization will be compared with fibrin glue for conjunctival autografting in primary pterygium surgery.

Interventions

PROCEDURECauterization

To ensure the stability of the graft during cuttings, four sealing wraps will be installed, which will be removed after cauterisation is completed. Autograft and conjunctiva will be approximated by surgical forceps and will be cauterized using a bipolar cutter (Erbe ICC 50) with a force 1-3 / 20. Forceps will be released slowly to prevent elevation of the graft. The same procedure will be performed 10 times until graft is well firmed. Graft stability will be checked up with a sponge and additional cauterization will be preformed if needed.

PROCEDUREFibrin glue

Fiber adhesive (Tissel 1 mL kit4-iu) will be prepared according to manufacturer's instructions. Preparation time will be approximately 10-15 min per kit. Once mixed the fibrin glue is usable up to 4 h. For the purpose of the study preparation of the fibrin glue will be performed by a nurse.

Sponsors

University Hospital of Split
CollaboratorOTHER
University of Split, School of Medicine
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)

Masking description

Surgeons will not be blinded. All the other investigators, as well as study participants, outcome assessors and author that will analyze the data will be blinded.

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* adults (older than 18 years of age) * both sexes * primary nasal pterygia ˃4 mm, which tends to increase, including patients with reduced visual acuity, chronic inflammation, cosmetic reasons * if the patients had a bilateral pterygium, only one eye will be operated

Exclusion criteria

* connective tissue disease * prior eye surgery * chronic use of topical drugs (anti-glaucoma drugs)

Design outcomes

Primary

MeasureTime frameDescription
Recurrence of pterygium180 daysAny re-growth of tissue from the area of excision across the limbus onto the cornea.

Secondary

MeasureTime frameDescription
Surgical timeDuring the surgerySurgical time: total operational time required for completion of the operation (measured in minutes)
Complication rate7, 30 and 180 daysComplication rate will be analyzed as the occurrence of at least one of the following major complications such as dehiscence, displacement or loss of the autograft, infection, haemorrhage, oedema, fibrosis, retraction and other indications that required special treatment
Pterygium-induced astigmatism7, 30 and 180 daysMeasured as described by Hsu 2014
Ocular surface condition7, 30 and 180 daysThe Ocular Surface Disease Index (OSDI) is a 12-question validated questionnaire used to measure ocular symptoms, visual function, and environmental factors that may affect a patient's vision. The OSDI scoring scale ranges from 0 to 100. The lower the score, the more symptomatic relief from dry eye symptoms a patient experiences. Baseline-adjusted scores were tabulated; a negative number change from baseline indicates a perceived improvement in ocular comfort.
Postoperative discomfort, tearing, pain and foreign body sensation7, 30 and 180 daysUsing modified scale from Lim Bon Siong et al: (0) none, no pain, (1) very mild, (2) mild, pain causing some discomfort, (3) moderate, pain that partially interferes with usual activity or sleep, (4) sever, pain that completely interferes with usual activity or sleep.
Pain7, 30 and 180 daysNumerical rating scale (NRS) ranging from 0 to 10, where 0 = No pain and 10 = Pain as intense as you can imagine.
Economic Analysis180 daysCost of each intervention
Flap timeDuring the surgeryTime needed for preparing and repositioning of the conjunctival grafts (measured in minutes)

Countries

Croatia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 24, 2026